Allogene appoints Geoffrey Parker as CFO effective Oct 16, 2023

Allogene Therapeutics, Inc.

Geoffrey Parker named EVP, CFO, Principal Financial & Accounting Officer, effective Oct 16, 2023.
Previously COO/CFO at Tricida, CFO at Anacor (sold to Pfizer for $5.2B), MD at Goldman Sachs.
Receives $490k base salary, 45% target bonus pro-rated for 2023, option for 950k shares, 400k RSUs.
Also eligible for performance RSUs of 390k shares tied to $18 stock price or first FDA approval by 2028.
Severance under CIC Plan: 18 months salary on change-in-control termination; 12 months on involuntary termination.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Geoffrey Parker

Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

ALLO · Allogene Therapeutics, Inc.

Effective: 2023-10-16
Filed: October 16, 2023, 7:59 PM ET

The Board of Directors of Allogene Therapeutics, Inc. (the “Company”) appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Geoffrey Parker was appointed as Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Allogene Therapeutics, Inc..

Action: appointed
Role: Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

Exact text from the filing

The Board of Directors of Allogene Therapeutics, Inc. (the “Company”) appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023.

View on SEC.gov

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-23-000079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.